leadf
logo-loader
viewRUA Life Sciences

AorTech International: Accelerating development of its novel heart valve and graft products

AorTech International plc's (LON:AOR) Bill Brown introduces the company to Proactive London's Andrew Scott.

He says the business is based on a platform technology material called Elast-Eon which he says has been in human use for close to 15 years.

They licence out the tech as well as develop their own products using it.

He says they've now begun the manufacture of heart valves and early prototype valves are currently available for evaluation plus they're also nearing animal trials for its graft development programme.

Quick facts: RUA Life Sciences

Price: 151 GBX

AIM:RUA
Market: AIM
Market Cap: £33.5 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Alpha Growth's BlackOak Alpha Growth Fund generates positive returns despite...

Alpha Growth PLC (LON:ALGW) (OTCQB: ALPGF) CEO Gobind Sahney tells Proactive the financial services specialist's BlackOak Alpha Growth Fund produced a 2020 calendar year return of 10.63% and a 13.71% total return since inception in September 2019. Sahney says given the challenges of 2020, its...

1 day, 15 hours ago

2 min read